Gu Garrick Han, Pauplis Connor, Seacor Taylor, Devuni Deepika, Krishnarao Anita
Internal Medicine, UMass Memorial Health, Worcester, United States.
Internal Medicine, UMass Chan Medical School, Worcester, United States.
Endosc Int Open. 2025 Apr 4;13:a25501468. doi: 10.1055/a-2550-1468. eCollection 2025.
We investigated the effect of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist therapy, on retained gastric contents during endoscopy through a retrospective case-control study.
We performed a retrospective case-control study to evaluate the effect of semaglutide on rates of retained gastric contents (RGC) visualized during esophagogastroduodenoscopy (EGD). Cases and controls were matched using multidimensional propensity score matching: age, gender, body mass index, and EGD indication. Pairs were analyzed using McNemar testing and Mann-Whitney non-parametric tests.
Of the patients on GLP-1 therapy at time of EGD, 12.5% had RGC, compared with 1.3% in the control group (confidence interval [CI] 7.2% to 17.7%, < 0.0001). Approximately 23% of patients prescribed GLP-1 therapy for weight loss had RGC at time of EGD compared with the control group (CI 13.4% to 32.6%, < 0.0001). Only 2.6% of patients prescribed GLP-1 therapy for diabetes had RGC at time of EGD compared with the control group (CI -0.9% to 6.1%, = 0.5). Patients receiving GLP-1 therapy with RGC at time of EGD did not differ from non-RGC patients in dosing of GLP-1 agonist ( = 0.23) or duration of GLP-1 agonist use prior to EGD ( = 0.98).
Semaglutide use appears to increase risk of having retained gastric contents visualized during endoscopy. Patients on semaglutide for weight loss appear to have a greater risk of RGC compared with patients on semaglutide for glycemic control. This observation may have clinical implications for management of GLP-1 agonist use prior to endoscopy.
我们通过一项回顾性病例对照研究，调查了胰高血糖素样肽-1（GLP-1）激动剂司美格鲁肽治疗对内镜检查期间胃内残留内容物的影响。
我们进行了一项回顾性病例对照研究，以评估司美格鲁肽对食管胃十二指肠镜检查（EGD）期间可见的胃内残留内容物（RGC）发生率的影响。病例和对照使用多维度倾向评分匹配：年龄、性别、体重指数和EGD指征。采用McNemar检验和Mann-Whitney非参数检验对配对进行分析。
在EGD检查时接受GLP-1治疗的患者中，12.5%有胃内残留内容物，而对照组为1.3%（置信区间[CI]7.2%至17.7%，P<0.0001）。与对照组相比，约23%因减肥而接受GLP-1治疗的患者在EGD检查时有胃内残留内容物（CI 13.4%至32.6%，P<0.0001）。与对照组相比，仅2.6%因糖尿病而接受GLP-1治疗的患者在EGD检查时有胃内残留内容物（CI -0.9%至6.1%，P = 0.5）。在EGD检查时出现胃内残留内容物的接受GLP-1治疗的患者与未出现胃内残留内容物的患者在GLP-1激动剂剂量（P = 0.23）或EGD检查前GLP-1激动剂使用持续时间（P = 0.98）方面无差异。
使用司美格鲁肽似乎会增加内镜检查期间可见胃内残留内容物的风险。与接受司美格鲁肽控制血糖的患者相比，接受司美格鲁肽减肥的患者出现胃内残留内容物的风险似乎更高。这一观察结果可能对内镜检查前GLP-1激动剂的使用管理具有临床意义。
